PT2260053E - Análogos de oxitocina - Google Patents

Análogos de oxitocina Download PDF

Info

Publication number
PT2260053E
PT2260053E PT97270318T PT09727031T PT2260053E PT 2260053 E PT2260053 E PT 2260053E PT 97270318 T PT97270318 T PT 97270318T PT 09727031 T PT09727031 T PT 09727031T PT 2260053 E PT2260053 E PT 2260053E
Authority
PT
Portugal
Prior art keywords
oxitocin
analogs
Prior art date
Application number
PT97270318T
Other languages
English (en)
Portuguese (pt)
Inventor
Claudio Schteingart
Sudarkodi Alagarsamy
Robert Galyean
Kazimierz Wisniewski
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2260053(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PT2260053E publication Critical patent/PT2260053E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
PT97270318T 2008-03-31 2009-03-30 Análogos de oxitocina PT2260053E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4097308P 2008-03-31 2008-03-31
EP08251739 2008-05-19

Publications (1)

Publication Number Publication Date
PT2260053E true PT2260053E (pt) 2014-08-29

Family

ID=39722695

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97270318T PT2260053E (pt) 2008-03-31 2009-03-30 Análogos de oxitocina

Country Status (20)

Country Link
US (1) US8673841B2 (enExample)
EP (2) EP2260053B1 (enExample)
JP (1) JP5539310B2 (enExample)
KR (1) KR101558404B1 (enExample)
CN (1) CN101983205B (enExample)
AU (1) AU2009233429B2 (enExample)
BR (1) BRPI0910345B1 (enExample)
CA (1) CA2718148C (enExample)
DK (1) DK2260053T3 (enExample)
ES (1) ES2488992T3 (enExample)
HR (1) HRP20140716T1 (enExample)
IL (1) IL208039A (enExample)
MX (1) MX2010010743A (enExample)
NZ (1) NZ587817A (enExample)
PL (1) PL2260053T3 (enExample)
PT (1) PT2260053E (enExample)
RU (1) RU2496788C2 (enExample)
SI (1) SI2260053T1 (enExample)
WO (1) WO2009122285A1 (enExample)
ZA (1) ZA201006733B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853158B2 (en) 2010-05-25 2014-10-07 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
NZ708175A (en) 2012-12-21 2020-06-26 Hoffmann La Roche Peptides as oxytocin agonists
CA2949173A1 (en) 2014-06-03 2015-12-10 Caterina Bissantz Peptides as oxytocin agonists
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RS65144B1 (sr) 2014-09-19 2024-02-29 Ferring Bv Postupak za lečenje prader-vilijevog sindroma
CN106084015B (zh) * 2016-08-25 2020-01-31 成都圣诺生物制药有限公司 一种合成卡贝缩宫素的方法
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
AU2018312956B2 (en) * 2017-08-11 2022-03-10 Ferring B.V. Method of manufacturing a pharmaceutical composition
CN107628975B (zh) * 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
WO2021089554A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
WO2022026463A1 (en) * 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Oxytocin analogues and methods for using the same
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DK1480998T3 (da) * 2002-02-27 2007-03-26 Ferring Bv Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger

Also Published As

Publication number Publication date
DK2260053T3 (da) 2014-06-23
JP5539310B2 (ja) 2014-07-02
WO2009122285A8 (en) 2009-12-10
CN101983205B (zh) 2015-08-19
CA2718148A1 (en) 2009-10-08
IL208039A (en) 2016-03-31
US8673841B2 (en) 2014-03-18
HRP20140716T1 (hr) 2014-08-29
EP2260053A1 (en) 2010-12-15
PL2260053T3 (pl) 2014-11-28
BRPI0910345A2 (pt) 2015-10-06
EP2626364A1 (en) 2013-08-14
WO2009122285A1 (en) 2009-10-08
RU2010139634A (ru) 2012-05-10
SI2260053T1 (sl) 2014-08-29
KR101558404B1 (ko) 2015-10-08
KR20110005705A (ko) 2011-01-18
EP2260053B1 (en) 2014-05-14
RU2496788C2 (ru) 2013-10-27
BRPI0910345B1 (pt) 2021-08-17
AU2009233429B2 (en) 2014-02-13
CA2718148C (en) 2017-11-07
HK1146064A1 (en) 2011-05-13
US20110044905A1 (en) 2011-02-24
CN101983205A (zh) 2011-03-02
AU2009233429A1 (en) 2009-10-08
ZA201006733B (en) 2011-06-29
ES2488992T3 (es) 2014-09-01
IL208039A0 (en) 2010-12-30
NZ587817A (en) 2012-05-25
JP2011516460A (ja) 2011-05-26
MX2010010743A (es) 2010-11-04

Similar Documents

Publication Publication Date Title
SMT201400023B (it) Analoghi di buprenorfina
BRPI0922508A2 (pt) Análogos de nucleosídeo
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI0823379A2 (pt) Análogos de glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
EP2519525A4 (en) SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
BRPI1005525A2 (pt) compostos de azaazuleno
PT2506716T (pt) Novos compostos tricíclicos
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
BRPI0910345A2 (pt) análogos de oxitocina
EP2510089A4 (en) SYNTHESIS OF PRAZOL COMPOUNDS
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
UY33156A (es) Nuevos compuestos tienopirrol
EP2110789A4 (en) PAPER MONEY PROCESSOR
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0916432A2 (pt) compostos
PT2492266E (pt) Derivado de 5-hidroxipirimidino-4-carboxamida
EP2479211A4 (en) FLUOR RUBBER COMPOSITION